F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES for F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Pandemic preparedness, accutane safety, diabetes issues, general pharmaceutical issues; federal lobbying on Tamiflu; pandemic flu funding; HR1585, the FIT Kids Act; issues addressing childhood obesity; track and monitor health care reform including H.R. 1427 and S.726, promoting Innovation and Access to Life-Saving Medicine Act; HR 1105 omnibus Approporiation Act; FY10 Labor HHS Approporiations legislation; community relations and outreach to develop and maintain relationships with minority groups and health organizations to promote diabetes awareness. Public policy such as promoting initiatives and strategizing on the most effective approaches to tell the story of Roche's efforts to address and try to resolve health disparities affecting minority communities; Federal lobbying on Tamiflu.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director of Federal Government Affairs |
| ANNA GRIFFIN | Director of Federal Government Affairs |
| EVAN MORRIS | VP of Fed.Government Affairs & Public Policy |
| JAMES SCOTT | Director of Federal Government Affairs |
Medicare/Medicaid MMM
Reimbursement and other issues related to anemia and arthritis drugs; planning treatment protocols for patients diabetes drugs.; HR 2, SCHIP Bill, issues related childhood obesity; Medicare coverage policy for blood glucose monitors and test strips; dynamic scoring; healthcare reform legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BARNETT | Director, Diagnostics |
| KATHLEEN A CLAESSENS | Director, Diagnostics |
| JAMES SCOTT | Director, Federal Government Affairs |
| BRUCE THOMAS TAYLOR | Director, Diagnostics |
Budget/Appropriations BUD
S. Con Res 13/H. Con Res 85, FY 2010 budget resolution, specific issues concerning budget assumptions related to prescription drug pricing and Medicare reimbursement. H.R.1, The American Recovery Reimbursement Act, as it relates to compative effectiveness and related funding and pandemic flu preparedness; issues related to government purchases of pandemic drugs - Tamiflu.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES SCOTT | Director of Federal Government Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.